SOURCE: Industrial Biotechnology Corp.

April 06, 2007 11:08 ET

Industrial Biotechnology Corporation Announces Engagement of Investor Relations Firm, Designated Marketing LLC

SARASOTA, FL -- (MARKET WIRE) -- April 6, 2007 -- Industrial Biotechnology (PINKSHEETS: IBTY) is pleased to announce the engagement of investor relations firm, Designated Marketing LLC, based in Frisco, Texas. Designated Marketing will assume all direct shareholder communications, as well as developing additional shareholder awareness for the company.

Dave West, CFO, says, "We are happy to have Designated Marketing LLC come on board. They will do a great job of updating our current shareholders as well as expanding our overall institutional and individual investor awareness."

About Designated Marketing LLC

Designated Marketing LLC (Designated) is a full-service financial communications and investor relations firm that specializes in micro/small-cap companies. Designated Marketing provides expert consulting services and customized proactive investor relations awareness campaigns. They design and implement direct mail, electronic marketing, shareholder communications and other programs to increase market awareness and overall shareholder communications on behalf of our clients. They will be working with Industrial Biotechnology Corporation in disseminating news and reports to its current shareholders as well as introducing the stock to potential new shareholders. Current shareholders and potential interested investors are encouraged to contact Designated Marketing to receive information at 972-731-5112 Ext 104 or 107.

About Industrial Biotechnology Corporation

Industrial Biotechnology Corporation (IBC) enables the biological production of chemicals through a combination of licensed patents, intellectual property and proprietary systems. We accomplish this through our ALCHEMx™ Productions Platforms, which are a systematic, streamlined approach to biologically manufacture chemicals more efficiently, at significantly lower costs, and with substantially lower environmental impact than traditional methods. IBC and its partners plan to produce and market new and established biologically produced chemicals to the pharmaceutical, bio-energy, agricultural, biopesticides, fine chemicals, flavors and fragrances, cosmeceuticals, biomaterials and biopolymer industries. For more information about Industrial Biotechnology Corporation, please visit its website at

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contact:
    Investor Relations
    972-731-5112 ext 104